BioArctic AB (STO:BIOA-B) a Swedish research-based biopharma company focused on innovative treatments for neurodegenerative diseases, announced on Thursday that it will publish its second quarter report for April-June 2025 on Thursday, August 28, 2025, at 08:00 a.m. CET.
Investors, analysts, and media are invited to an audiocast with teleconference (in English) on August 28, at 09:30 CET, where BioArctic CEO Gunilla Osswald, CFO Anders Martin-Lof, and colleagues will present and comment on the second quarter report, followed by a Q&A session.
Those wishing to participate via webcast can do so at https://bioarctic.events.inderes.com/q2-report-2025/register. Written questions can be asked via the webcast.
To participate via teleconference, register at https://events.inderes.com/bioarctic/q2-report-2025/dial-in to receive a phone number and conference ID. Those participating via teleconference can ask questions verbally during the event.
The webcast will also be available on demand on BioArctic's corporate website https://www.bioarctic.com/en/investors/financial-reports-and-presentations/ after the presentation.
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Lighthouse Pharmaceuticals announces receipt of USD49.2m grant from NIA for LHP588 study
Innovent Biologics receives approval over squamous cell lung cancer study
Cambrex announces expansion of peptide manufacturing capabilities in Waltham, Massachusetts
Tyra Biosciences doses first child in dabogratinib Phase 2 achondroplasia clinical study
Crinetics Pharmaceuticals' atumelnant granted US FDA Orphan Drug Designation
BioArctic schedules Q2 2025 report
Nicox announces NCX 470 met primary objective in Phase 3 clinical trial
Hamlet BioPharma completes Phase II study of Alpha1H in non-muscle invasive bladder cancer